UC-112 is a survivin and XIAP modulator that exhibits anticancer activity. It selectively downregulates and degrades survivin through the ubiquitin-mediated proteasomal degradation pathway and also reduces XIAP levels in in vivo tumor models. UC-112 activates caspase-3/7 and caspase-9, leading to cancer cell apoptosis. It is suitable for studies related to melanoma, prostate cancer, and other cancer research.
- Selectively downregulates and degrades survivin via the ubiquitin-mediated proteasomal degradation pathway.
- Reduces XIAP levels in in vivo tumor models.
- Activates caspase-3/7 and caspase-9, inducing cancer cell apoptosis.
- Applicable to studies on melanoma, prostate cancer, and cancer-related research.
- Potently inhibits proliferation of A375, M14, PC-3, and DU145 cancer cells.
- Alters cell cycle distribution of A375 melanoma cells.